Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 10 vs CHOLESTYRAMINE LIGHT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
FDA: Primary hyperlipidemia (Fredrickson Type IIa) as adjunctive therapy to diet to reduce elevated serum LDL cholesterol,FDA: Relief of pruritus associated with partial biliary obstruction or primary biliary cirrhosis,Off-label: Diarrhea associated with bile acid malabsorption (e.g., post-cholecystectomy diarrhea, Crohn's disease),Off-label: Digoxin toxicity (to interrupt enterohepatic circulation, though rarely used today)
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
Not metabolized; acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
Not applicable (non-absorbed); no plasma protein binding.
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
Not applicable (non-absorbed); confined to gastrointestinal lumen.
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
Oral: <0.04% (minimal systemic absorption due to large molecular weight and quaternary ammonium structure).
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
No dosage adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
No specific dosage adjustment recommended; caution in patients with severe hepatic impairment.
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
240 mg/kg/day orally in 2-3 divided doses, not to exceed 8 g/day; adjust based on clinical response.
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
Start at low end of dosing range (4 g/day) and titrate slowly; monitor for constipation and drug interactions.
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
No FDA boxed warning.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
May reduce absorption of fat-soluble vitamins (A, D, E, K), requiring supplementation,May cause hyperchloremic metabolic acidosis, especially in children with large doses,May cause constipation, which can aggravate hemorrhoids; discontinue if impaction occurs,May interfere with absorption of other drugs; administer other medications at least 1 hour before or 4-6 hours after cholestyramine,Use with caution in patients with phenylketonuria (products may contain aspartame)
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
Complete biliary obstruction (ineffective and may cause harm),Hypersensitivity to cholestyramine or any component of the formulation
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
Cholestyramine binds to bile acids in the gut and can also bind to dietary fats and fat-soluble vitamins. Administer with food to reduce GI side effects. High-fat meals may reduce efficacy by competing for binding. Avoid concurrent intake with grapefruit juice (may alter binding). Separate ingestion from high-fat, large meals by at least 1 hour.
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
Cholestyramine is a non-absorbed resin; systemic absorption is negligible. No teratogenic effects reported in animal studies or human case reports. Risk to fetus is minimal across all trimesters.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
Breastfeeding safety: Compatible due to negligible systemic absorption. M/P ratio: Not applicable (not absorbed). No adverse effects reported in breastfed infants.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
No dose adjustment required in pregnancy due to lack of systemic absorption. Ensure adequate intake of fat-soluble vitamins and consider folic acid supplementation due to potential binding.
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
Cholestyramine Light contains aspartame; contraindicated in phenylketonuria. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine to reduce binding. Monitor for hyperchloremic metabolic acidosis, especially in renal impairment. Constipation is common; encourage fluid intake. May reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
Take exactly as prescribed, usually mixed with water or non-carbonated liquid; do not swallow dry powder.,Take other medications at least 1 hour before or 4-6 hours after cholestyramine to ensure proper absorption.,Drink plenty of fluids and eat fiber-rich foods to prevent constipation.,Report unusual bleeding, bruising, or dark urine (signs of vitamin K deficiency).,This product contains aspartame; avoid if you have phenylketonuria.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 10 vs CHOLESTYRAMINE LIGHT, answered by our medical review team.
ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. CHOLESTYRAMINE LIGHT is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 10 and CHOLESTYRAMINE LIGHT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. The standard adult dose of CHOLESTYRAMINE LIGHT is: 4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 10 and CHOLESTYRAMINE LIGHT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. CHOLESTYRAMINE LIGHT is classified as Category C. Cholestyramine is a non-absorbed resin; systemic absorption is negligible. No teratogenic effects reported in animal studies or human case reports. Risk to fetus is minimal across . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.